Neogenomics Inc (NEO)

$7.91 -0.27 (-3.30%)
Market Cap 1.06B
Revenue (ttm) 727.33M
Net Income (ttm) -108.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14.85%
Debt to Equity Ratio 0.00
Volume 1,987,500
Avg Vol 1,975,810
Day's Range N/A - N/A
Shares Out 130.14M
Stochastic %K 26%
Beta 1.72
Analysts Sell
Price Target $14.19

Company Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the pr...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 239 768 0600
Fax: 239 690 4237
Address:
9490 NeoGenomics Way, Fort Myers, United States
FillSniper42
FillSniper42 Apr. 23 at 7:10 PM
IQST is bottomed out with an upcoming product launch and severely undervalued.. - No dilution - $300M+ yearly revenue with 1B+ forecasted for 2027 - $18 Price Target by litchfield (currently trading under $2) $BBAI $SOUN $AI $NEO $XPEV www
0 · Reply
Kat_Harington
Kat_Harington Apr. 23 at 5:59 PM
$NEO chart looking good as usual
0 · Reply
UltimateGuardians
UltimateGuardians Apr. 23 at 1:43 AM
$NEO long it now and win
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 16 at 6:14 AM
$NEO Share Price: $8.69 Contract Selected: Nov 20, 2026 $12.0 Calls Buy Zone: $0.46 – $0.57 Target Zone: $0.78 – $0.95 Potential Upside: 60% ROI Time to Expiration: 218 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Kat_Harington
Kat_Harington Apr. 10 at 6:36 PM
$NEO bag holder for life
0 · Reply
Joicewilly
Joicewilly Mar. 31 at 9:19 AM
Something interesting happening in energy storage right now. A U.S. company, Unigrid, is pushing sodium-ion batteries that could last up to 25 years, basically matching the lifespan of solar panels. That’s a big deal if it holds up, fewer replacements, more predictable costs. At the same time, you’ve got iron-sodium batteries being developed with fully domestic materials, flow batteries scaling in Europe, and even thermal storage systems turning waste heat into usable energy. Source: https://www.energy-storage.news/roundup-non-lithium-energy-storage-system-technology-advances-in-us-spain-and-scotland/ $FLNC $STEM $NEO $SQS
1 · Reply
DriveForShow
DriveForShow Mar. 30 at 2:47 PM
$NEO Down almost 42% in last 90 days. Still no bottom yet.
1 · Reply
Kat_Harington
Kat_Harington Mar. 27 at 6:01 PM
$NEO this thing is toast
1 · Reply
DriveForShow
DriveForShow Mar. 26 at 5:30 PM
$NEO The never ending bottom. Agonizing
0 · Reply
ArtisanPalaceTrades
ArtisanPalaceTrades Mar. 26 at 12:28 AM
$NEO its time to run i think
1 · Reply
Latest News on NEO
NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

Apr 23, 2026, 7:05 AM EDT - 1 day ago

NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026

Apr 13, 2026, 7:05 AM EDT - 11 days ago

NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026

NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026

Apr 7, 2026, 7:05 AM EDT - 17 days ago

NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026

NeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling

Mar 16, 2026, 7:05 AM EDT - 5 weeks ago

NeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling

NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types

Feb 25, 2026, 7:05 AM EST - 2 months ago

NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types

NeoGenomics to Participate in Upcoming Investor Conferences

Feb 18, 2026, 7:05 AM EST - 2 months ago

NeoGenomics to Participate in Upcoming Investor Conferences

NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

Feb 17, 2026, 7:05 AM EST - 2 months ago

NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection

Feb 12, 2026, 7:05 AM EST - 2 months ago

NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection

NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Jan 27, 2026, 7:05 AM EST - 3 months ago

NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

Jan 12, 2026, 7:05 AM EST - 3 months ago

NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:05 AM EST - 3 months ago

NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors

Dec 30, 2025, 7:05 AM EST - 4 months ago

NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors

NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation

Dec 15, 2025, 7:05 AM EST - 4 months ago

NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation

NeoGenomics to Present New ctDNA Research at SABCS 2025

Dec 10, 2025, 7:05 AM EST - 4 months ago

NeoGenomics to Present New ctDNA Research at SABCS 2025

NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025

Dec 8, 2025, 8:05 AM EST - 4 months ago

NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025

NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors

Oct 30, 2025, 12:51 PM EDT - 6 months ago

NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors

NeoGenomics Reports Third Quarter 2025 Results

Oct 28, 2025, 7:05 AM EDT - 6 months ago

NeoGenomics Reports Third Quarter 2025 Results

NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025

Oct 14, 2025, 7:05 AM EDT - 6 months ago

NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025

NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025

Oct 7, 2025, 7:05 AM EDT - 7 months ago

NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025

NeoGenomics Stock In A Range-Bound Matrix, Weakness Likely Until 2026

Sep 17, 2025, 7:58 AM EDT - 7 months ago

NeoGenomics Stock In A Range-Bound Matrix, Weakness Likely Until 2026

NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

Aug 29, 2025, 1:04 PM EDT - 8 months ago

NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera

Aug 29, 2025, 7:05 AM EDT - 8 months ago

Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera

NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy

Jul 30, 2025, 7:05 AM EDT - 9 months ago

NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy

NeoGenomics Reports Second Quarter 2025 Results

Jul 29, 2025, 7:05 AM EDT - 9 months ago

NeoGenomics Reports Second Quarter 2025 Results

NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

Jul 1, 2025, 7:05 AM EDT - 10 months ago

NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care

Jun 30, 2025, 7:05 AM EDT - 10 months ago

NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

Jun 24, 2025, 7:05 AM EDT - 10 months ago

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025

May 28, 2025, 7:10 AM EDT - 11 months ago

NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025

NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer

May 22, 2025, 7:10 AM EDT - 1 year ago

NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer

NeoGenomics to Participate in Upcoming June Investor Conferences

May 20, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics to Participate in Upcoming June Investor Conferences

NeoGenomics Pays Off 1.25% Convertible Senior Notes

May 1, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Pays Off 1.25% Convertible Senior Notes

NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

Apr 29, 2025, 8:00 AM EDT - 1 year ago

NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

NeoGenomics Reports First Quarter 2025 Results

Apr 29, 2025, 7:30 AM EDT - 1 year ago

NeoGenomics Reports First Quarter 2025 Results

NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

Apr 22, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

Apr 8, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

NeoGenomics Completes Acquisition of Pathline

Apr 7, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Completes Acquisition of Pathline

Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

Apr 1, 2025, 7:05 AM EDT - 1 year ago

Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

Mar 10, 2025, 7:00 AM EDT - 1 year ago

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

NeoGenomics Reports Fourth Quarter and Full Year 2024 Results

Feb 18, 2025, 7:05 AM EST - 1 year ago

NeoGenomics Reports Fourth Quarter and Full Year 2024 Results

NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025

Jan 29, 2025, 8:05 AM EST - 1 year ago

NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025

NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan

Jan 15, 2025, 7:05 AM EST - 1 year ago

NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan

NeoGenomics Announces Chief Executive Officer Succession

Jan 10, 2025, 7:05 AM EST - 1 year ago

NeoGenomics Announces Chief Executive Officer Succession

NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 7:55 AM EST - 1 year ago

NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma

Dec 11, 2024, 8:05 AM EST - 1 year ago

NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma

FillSniper42
FillSniper42 Apr. 23 at 7:10 PM
IQST is bottomed out with an upcoming product launch and severely undervalued.. - No dilution - $300M+ yearly revenue with 1B+ forecasted for 2027 - $18 Price Target by litchfield (currently trading under $2) $BBAI $SOUN $AI $NEO $XPEV www
0 · Reply
Kat_Harington
Kat_Harington Apr. 23 at 5:59 PM
$NEO chart looking good as usual
0 · Reply
UltimateGuardians
UltimateGuardians Apr. 23 at 1:43 AM
$NEO long it now and win
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 16 at 6:14 AM
$NEO Share Price: $8.69 Contract Selected: Nov 20, 2026 $12.0 Calls Buy Zone: $0.46 – $0.57 Target Zone: $0.78 – $0.95 Potential Upside: 60% ROI Time to Expiration: 218 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Kat_Harington
Kat_Harington Apr. 10 at 6:36 PM
$NEO bag holder for life
0 · Reply
Joicewilly
Joicewilly Mar. 31 at 9:19 AM
Something interesting happening in energy storage right now. A U.S. company, Unigrid, is pushing sodium-ion batteries that could last up to 25 years, basically matching the lifespan of solar panels. That’s a big deal if it holds up, fewer replacements, more predictable costs. At the same time, you’ve got iron-sodium batteries being developed with fully domestic materials, flow batteries scaling in Europe, and even thermal storage systems turning waste heat into usable energy. Source: https://www.energy-storage.news/roundup-non-lithium-energy-storage-system-technology-advances-in-us-spain-and-scotland/ $FLNC $STEM $NEO $SQS
1 · Reply
DriveForShow
DriveForShow Mar. 30 at 2:47 PM
$NEO Down almost 42% in last 90 days. Still no bottom yet.
1 · Reply
Kat_Harington
Kat_Harington Mar. 27 at 6:01 PM
$NEO this thing is toast
1 · Reply
DriveForShow
DriveForShow Mar. 26 at 5:30 PM
$NEO The never ending bottom. Agonizing
0 · Reply
ArtisanPalaceTrades
ArtisanPalaceTrades Mar. 26 at 12:28 AM
$NEO its time to run i think
1 · Reply
carminefox
carminefox Mar. 19 at 2:23 PM
$NEO I'm guessing this is just following the market at this point
0 · Reply
getem2011
getem2011 Mar. 16 at 2:53 PM
$NEO this thing has been amazing for swings. I’ve followed this company for the last 20 years and still believe long-term. It will be very successful.
0 · Reply
carminefox
carminefox Mar. 13 at 9:22 PM
$NEO bag holding this patiently. Hoping for that buy out offer!
0 · Reply
Fabiola_T
Fabiola_T Mar. 13 at 1:08 PM
$NEO lower high set
0 · Reply
DriveForShow
DriveForShow Mar. 12 at 5:04 PM
$NEO Did we finally hit a new bottom?
0 · Reply
Kat_Harington
Kat_Harington Mar. 12 at 2:22 PM
$NEO this thing is DUMPING
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 8:40 PM
$NEO Current Stock Price: $8.55 Contracts to trade: $9.0 NEO Mar 20 2026 Call Entry: $1.10 Exit: $1.69 ROI: 54% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Kat_Harington
Kat_Harington Mar. 9 at 2:16 PM
$NEO haven’t seen a green day in months.
1 · Reply
IN0V8
IN0V8 Mar. 6 at 2:33 PM
$NEO Added at $8.95
0 · Reply
IN0V8
IN0V8 Mar. 2 at 5:49 PM
$NEO added at $9.2
0 · Reply
DriveForShow
DriveForShow Mar. 2 at 3:05 PM
$NEO Figured the 200MA would get tested and it’s just about there. Will it hold $9.23?
0 · Reply
GordoHLYK13
GordoHLYK13 Feb. 27 at 11:14 AM
$NEO 🚀 Why NeoGenomics ($NEO) is Moving Today 1. The "Big Win": RaDaR ST Official Launch After years of legal handcuffs, NeoGenomics officially launched its RaDaR ST assay this week. This is their "Natera-killer"—a high-sensitivity test for cancer recurrence in a market worth over $20 billion. 2. Legal "All-Clear" with Natera The lawsuit you saw regarding InVisionFirst-Lung was just settled. Combined with Natera dropping its major patent appeals in December, NeoGenomics now has zero major legal blockages for the first time in years. They are finally free to sell without fear of court injunctions. 3. Institutional "Relief Rally" The stock took a hit last week on 2026 guidance $NTRA 1️⃣ RaDaR ST Launch: Officially live this week to challenge Natera's dominance in the $20B cancer-tracking market. 2️⃣ Legal Peace: Settled the InVisionFirst suit with $NTRA; patent "war" is essentially over. 3️⃣ Commercial Era: No more courtroom drama—just pure growth and market share capture.
1 · Reply